-
Mashup Score: 1Beyonttra | European Medicines Agency (EMA) - 11 day(s) ago
On 12 December 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Beyonttra 1, intended for the treatment of transthyretin amyloidosis in adult patients with cardiomyopathy. The applicant for this medicinal product is BridgeBio Europe B.V. Beyonttra will be available as 356 mg film-coated tablet. The active substance of BEYONTTRA is acoramidis hydrochloride, belonging to the pharmacothe
Source: www.ema.europa.euCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0TI Sr Clinical Research Associate in Portland, Oregon | Careers at Portland, OR (Waterfront) - 11 day(s) ago
The Senior Coordinator oversees all regulatory activities for each study in the program. This includes the following: IRB Protocol Management and Development – In collaboration leadership and based on sponsor protocol, develop and submit new IRB protocols for review. – Work in collaboration with coordinator teams and leadership to ensure timely closeout of all IRB protocols covering studies that have terminated – Work in collaboration with coordinator teams and leadership to ensure all IRB protocols are up to date, including updated staffing information, accurate term dates, and that amendments and continuing reviews are submitted timely when adjustments are needed. – Be the primary point of contact for IRB. Collaborate with study teams and leadership to submit changes, and address regulatory gaps with IRB protocols. Study Documentation – Monitor and ensure documentation storage meets FDA, institutional and sponsor guidelines. – Oversight and maintenance of all regulatory binders fo
Source: externalcareers-ohsu.icims.comCategories: General Medicine News, CardiologistsTweet-
We are expanding our team (again) and hiring for multiple positions from research assistants to associates. We focus on cardiomyopathies research, mainly clinical, imaging and translational. https://t.co/apDVcqRtJv https://t.co/m7Dq0QmTZq https://t.co/7KFEi9OBlj.… https://t.co/40bA1FoRhy https://t.co/jKMoPOUNti
-
-
Mashup Score: 4UB-MBX-46 is a potent and selective antagonist of the human P2X7 receptor developed by structure-based drug design - 12 day(s) ago
The P2X7 receptor is an ATP-gated ion channel that activates inflammatory pathways involved in diseases such as cancer, atherosclerosis, and neurodegeneration. However, despite the potential benefits of blocking overactive signaling, no P2X7 receptor antagonists have been approved for clinical use. Interspecies variation among existing antagonists has proven challenging, in part due to the dearth of molecular information on different receptor orthologs. Here, to identify distinct molecular features in the human receptor, we determine high-resolution cryo-EM structures of the full-length wild-type human P2X7 receptor in apo closed and ATP-bound open state conformations and draw comparisons with new and existing structures of other orthologs. We also report a cryo-EM structure of the human receptor in complex with an adamantane-based inhibitor, which we leverage, in conjunction with functional data and molecular dynamics simulations, to design a potent and selective antagonist with a uni
Source: www.biorxiv.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5The Critical Role of the Variable Domain in Driving Proteotoxicity and Aggregation in Full-length Light Chains - PubMed - 16 day(s) ago
Light chain (AL) amyloidosis is the most common systemic amyloid disease characterized by abnormal accumulation of amyloid fibrils derived from immunoglobulin light chains (LCs). Both full-length (FL) LCs and their isolated variable (VL) and constant (CL) domains contribute to amyloid deposits in mu …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 29
BACKGROUND: Distinguishing hypertrophic cardiomyopathy (HCM) from other cardiomyopathies with left ventricular hypertrophy (LVH), such as hypertensive LVH, transthyretin amyloid cardiomyopathy, and aortic stenosis, is sometimes challenging. Using plasma proteomics profiling, we aimed to identify circulating biomarkers and dysregulated signaling pathways specific to HCM. METHODS: In this multicenter case-control study, plasma proteomics profiling was performed in cases with HCM and controls with hypertensive LVH, transthyretin amyloid cardiomyopathy, and aortic stenosis. Two-thirds of patients enrolled earlier in each disease group were defined as the training set and the remaining one-third as the test set. Protein concentrations in HCM were compared with those in hypertensive LVH (comparison 1), transthyretin amyloid cardiomyopathy (comparison 2), and aortic stenosis (comparison 3). Candidate proteins that meet the following 2 criteria were selected: (1) higher abundance in HCM throug
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 23
Light chain (AL) amyloidosis is a serious systemic disease caused by the deposition of free misfolded immunoglobulin light chains (LCs) in the form of amyloid fibrils within tissues. Cardiac involvement determines prognosis and mortality. An …
Source: pmc.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 15Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies - 19 day(s) ago
Published in Amyloid: The Journal of Protein Folding Disorders (Ahead of Print, 2025)
Source: www.tandfonline.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 19Single‐Cell Transcriptomic Reveals the Involvement of Cell–Cell Junctions in the Early Development of Hypertrophic Cardiomyopathy - 21 day(s) ago
The relationship between the changes in endothelial cell–cell junctions and microvascular abnormalities in the progression of hypertrophic cardiomyopathy (HCM), as well as their potential as early bi…
Source: onlinelibrary.wiley.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 20Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten - 21 day(s) ago
Clinical Pharmacokinetics – Aficamten, a small-molecule, selective cardiac myosin inhibitor, is under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM)….
Source: link.springer.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 38Camzyos | European Medicines Agency (EMA) - 21 day(s) ago
Camzyos is a medicine used in adults to treat obstructive hypertrophic cardiomyopathy (oHCM), a disease in which the muscle in the main pumping chamber of the heart becomes thickened or enlarged, which can block the flow of blood from the heart to the rest of the body. It is used in adults who have symptoms of the disease (class II or class III oHCM). The ‘class’ reflects the seriousness of the disease: ‘class II’ involves slight limitation of physical activity and ‘class III’ involves marked limitation
Source: www.ema.europa.euCategories: General Medicine News, CardiologistsTweet
Acoramidis is Beyonttra in Europe US: Attruby #CardioTwitter https://t.co/XwsGpFb9pi. https://t.co/6bN8TkYZIm